1. A 54-year-old man with Parkinson's disease diagnosed 3 years ago is on pramipexole 1.5 mg three times daily as first-line therapy, with good motor control. His wife calls the clinic reporting that over the past 4 months he has developed compulsive online gambling, spending approximately $2,000 per week, has no insight into the problem, and becomes irritable when she raises it. He denies any behavioral change. Which of the following best explains the mechanism of this complication, identifies the pharmacological risk factor specific to dopamine agonists over levodopa, and describes the correct management approach?

• A) The gambling behavior represents pramipexole-induced frontal lobe disinhibition through excessive stimulation of D1 receptors in the dorsolateral prefrontal cortex, causing impaired executive control over reward-seeking behavior; levodopa shares this risk equally because it also produces D1 receptor stimulation via conversion to dopamine; management is dose reduction to below 0.75 mg three times daily, which reduces D1 stimulation below the threshold for frontal disinhibition.
• B) The gambling behavior is a manifestation of pramipexole-induced dopamine dysregulation syndrome — a form of behavioral addiction distinct from impulse control disorders — in which the patient compulsively self-escalates his pramipexole dose to achieve hedonic reward; management requires inpatient detoxification with supervised tapering and should not be attempted in the outpatient setting due to withdrawal dysphoria risk.
• C) The gambling behavior represents a direct pharmacological toxic effect of pramipexole's amphetamine metabolite, which accumulates in limbic dopaminergic pathways over months of chronic use; the risk is lower with levodopa because levodopa does not generate amphetamine metabolites; management is switching to levodopa and allowing 6 to 8 weeks for metabolite clearance before behavioral improvement occurs.
• D) Impulse control disorders (ICDs) — including pathological gambling, hypersexuality, compulsive eating, and compulsive shopping — occur in approximately 15 to 20% of PD patients on dopamine agonists and are attributed to preferential stimulation of D3 receptors in the mesolimbic reward circuitry (nucleus accumbens, ventral striatum); levodopa carries substantially lower ICD risk because its pulsatile striatal dopamine release is predominantly in the dorsal (motor) striatum, while agonists with high D3 affinity tonically stimulate the ventral reward circuitry; management requires reducing or discontinuing the agonist, typically with substitution of levodopa for motor control, and patient and family education that the behavior is drug-induced and generally resolves with agonist reduction.
• E) The gambling behavior represents serotonin syndrome from pramipexole's partial agonist activity at 5-HT2C receptors in the nucleus accumbens, which disinhibits mesolimbic dopamine release; levodopa does not carry this risk because it lacks 5-HT2C affinity; management is adding a 5-HT2C antagonist such as mirtazapine without reducing the pramipexole dose, as pramipexole reduction would worsen parkinsonian motor symptoms unacceptably.

2. A 70-year-old man with Parkinson's disease in a resource-limited setting has been managed for 2 years on levodopa 300 mg three times daily without carbidopa, with moderate motor control but persistent nausea. His general practitioner adds pyridoxine 50 mg daily based on a nutritional guideline recommending B6 supplementation in elderly patients. Three weeks later the patient returns with substantially worsened motor control — tremor has increased and bradykinesia has returned to near-baseline — despite unchanged levodopa dosing. His nausea, however, has paradoxically worsened further. Which of the following single explanation best accounts for both the motor deterioration and the worsening nausea simultaneously?

• A) Pyridoxine at 50 mg daily saturates CNS AADC with excess cofactor, dramatically increasing the rate of CNS levodopa conversion to dopamine, producing receptor desensitization through overstimulation that paradoxically reduces effective dopaminergic signaling at motor circuits while simultaneously increasing dopamine production in the area postrema and worsening nausea.
• B) Pyridoxine at 50 mg daily markedly increases peripheral AADC activity throughout the gut wall and systemic circulation by providing excess PLP cofactor, substantially accelerating peripheral conversion of levodopa to dopamine before it can cross the blood-brain barrier; the result is a large reduction in the fraction of each dose reaching the CNS as levodopa (explaining motor deterioration) and simultaneously a large increase in peripheral dopamine production stimulating area postrema D2 receptors (explaining worsened nausea) — both consequences of the same mechanism operating at the same peripheral site.
• C) Pyridoxine at 50 mg daily competitively inhibits LAT1 transport of levodopa at both the intestinal epithelium and the blood-brain barrier because pyridoxine is a large neutral amino acid structurally recognized by LAT1; the reduced CNS levodopa entry explains motor deterioration; the worsened nausea reflects accumulation of unabsorbed levodopa in the colon where bacterial AADC converts it to dopamine that is absorbed into the portal circulation and stimulates the area postrema.
• D) Pyridoxine at 50 mg daily inhibits hepatic COMT, diverting levodopa metabolism from O-methylation to the AADC pathway, increasing peripheral dopamine production that worsens nausea while reducing 3-O-methyldopa formation; because 3-OMD normally serves as a levodopa reservoir that slowly releases levodopa back into plasma, its reduction shortens effective levodopa duration and worsens motor control.
• E) Pyridoxine at 50 mg daily induces hepatic CYP2C9 expression, increasing first-pass oxidative metabolism of levodopa to an inactive catechol-quinone that cannot cross the blood-brain barrier; simultaneously, the quinone metabolite accumulates in the peripheral circulation and stimulates dopamine receptors in the area postrema with higher affinity than dopamine itself, producing the paradoxical combination of reduced CNS effect and worsened nausea.

3. A 67-year-old woman with Parkinson's disease on carbidopa/levodopa 25/100 mg six times daily develops progressive wearing-off despite the high dosing frequency. Her neurologist measures a plasma 3-O-methyldopa (3-OMD) level and finds it markedly elevated at 8.4 micromol/L (normal reference less than 2.0 micromol/L). The neurologist explains that 3-OMD accumulation is contributing to her wearing-off through a mechanism beyond simple levodopa half-life kinetics. Which of the following best explains how 3-OMD accumulation worsens levodopa's clinical effect and why entacapone addresses this specific problem?

• A) 3-OMD is a large neutral amino acid produced by peripheral COMT-mediated O-methylation of levodopa; because it shares the LAT1 transporter with levodopa at both the intestinal epithelium and the blood-brain barrier, chronically elevated plasma 3-OMD concentrations create a persistent competitive burden that reduces levodopa absorption from the gut and reduces levodopa entry into the CNS independent of plasma levodopa levels; 3-OMD has a plasma half-life of approximately 15 hours — far longer than levodopa's 1 to 3 hours — so it accumulates across multiple doses in patients on frequent dosing schedules, producing a sustained competitive disadvantage for levodopa that is not corrected by simply increasing levodopa dose or frequency; entacapone, by blocking peripheral COMT, reduces 3-OMD formation at each dose, lowering the steady-state 3-OMD burden and relieving the competitive pressure on LAT1-mediated levodopa transport.
• B) 3-OMD is a direct D2 receptor antagonist that accumulates in the striatum at high plasma concentrations and competitively blocks dopamine binding; its prolonged striatal half-life of approximately 15 hours means that each levodopa dose must overcome progressively higher receptor blockade as treatment frequency increases; entacapone addresses this by preventing 3-OMD formation, reducing striatal receptor blockade and allowing dopamine to bind D2 receptors at lower plasma concentrations.
• C) 3-OMD is metabolized back to levodopa by a peripheral methyltransferase reversal reaction, but at high plasma concentrations this reversal reaction saturates and 3-OMD instead undergoes irreversible conversion to a neurotoxic quinone that accelerates nigrostriatal degeneration; entacapone prevents quinone formation by blocking the initial COMT reaction, and its benefit in wearing-off reflects neuroprotection of remaining dopaminergic terminals rather than any pharmacokinetic effect.
• D) 3-OMD competitively inhibits aromatic amino acid decarboxylase (AADC) in the CNS by occupying the pyridoxal-5'-phosphate cofactor binding site with higher affinity than levodopa substrate, reducing the efficiency of CNS levodopa-to-dopamine conversion; entacapone restores AADC activity by reducing 3-OMD levels, allowing normal conversion rates to resume at lower levodopa concentrations.
• E) 3-OMD crosses the blood-brain barrier via a separate low-affinity transporter and is then converted to 3-methoxytyramine in dopaminergic neurons, which acts as a false neurotransmitter that is co-released with dopamine and blocks postsynaptic D1 receptors; entacapone prevents 3-methoxytyramine accumulation by blocking the precursor 3-OMD formation, restoring normal D1-mediated direct pathway activation.

4. A 76-year-old man with a 13-year history of Parkinson's disease has severe on-off fluctuations that have not responded to carbidopa/levodopa six times daily, entacapone at each dose, rasagiline 1 mg daily, and a trial of extended-release carbidopa/levodopa. A gastric emptying study confirms severe gastroparesis with 4-hour gastric half-emptying time. His neurologist explains that his gastroparesis is directly undermining all oral levodopa strategies and that a parenteral rescue agent is needed. Which of the following best explains why gastroparesis creates a therapeutic problem specifically resistant to oral pharmacokinetic optimization, and why subcutaneous apomorphine is the appropriate next step?

• A) Gastroparesis reduces gastric acid secretion, raising intragastric pH above 6.0 and causing levodopa to precipitate as an insoluble salt in the stomach; because levodopa is only soluble at pH below 4.5, none of the swallowed dose dissolves sufficiently for intestinal absorption regardless of dosing frequency; apomorphine bypasses this solubility problem by entering the systemic circulation directly through subcutaneous tissue without requiring dissolution in gastric fluid.
• B) Gastroparesis causes retrograde peristalsis that returns levodopa to the esophagus before it can reach the small intestine, exposing it to esophageal AADC which converts it entirely to dopamine before absorption; apomorphine avoids this by being absorbed sublingually rather than through the gastrointestinal tract, reaching the systemic circulation via the sublingual venous plexus without esophageal exposure.
• C) Gastroparesis eliminates the fasting state in the proximal small intestine by continuously delivering partially digested protein from the stomach, creating a permanent high-amino-acid environment at the LAT1 absorption site that blocks all levodopa uptake regardless of meal timing; apomorphine bypasses LAT1 entirely because it is not a large neutral amino acid and does not require transporter-mediated absorption.
• D) Gastroparesis causes levodopa to be absorbed through the colonic mucosa rather than the proximal jejunum after prolonged gastric retention; colonic absorption via passive diffusion is highly variable and produces erratic plasma levodopa levels; apomorphine is preferred because it is absorbed by active transport in the colon, providing more predictable pharmacokinetics when proximal intestinal absorption is compromised.
• E) Gastroparesis delays gastric emptying unpredictably, making levodopa delivery to the proximal jejunal LAT1 absorption site erratic and variable regardless of dosing schedule, dose size, formulation, or adjunctive COMT and MAO-B inhibition — all of which act downstream of the gastric emptying bottleneck that these strategies cannot address; subcutaneous apomorphine, a direct D1/D2 dopamine receptor agonist, bypasses the entire gastrointestinal pharmacokinetic pathway and produces a reliable, rapid on response within 5 to 15 minutes of injection, making it the appropriate rescue agent for refractory off episodes in patients whose oral pharmacokinetics are fundamentally compromised by gastroparesis.

5. A 69-year-old man with Parkinson's disease has been stable on carbidopa/levodopa IR 25/100 mg four times daily (total 400 mg levodopa per day) for 18 months. A covering physician switches him to carbidopa/levodopa CR 50/200 mg twice daily, noting that the total daily levodopa dose is now 400 mg — the same as before — and that twice-daily dosing should be more convenient. The patient returns 3 weeks later reporting clear wearing-off in the afternoons and evenings that was not present before the switch. His motor diary confirms 3 hours of additional off time per day compared with his pre-switch baseline. Which of the following most precisely identifies the pharmacokinetic error made in this conversion and the correct approach to rectify it?

• A) The error was switching to twice-daily dosing, which produces a dosing interval of 12 hours — far exceeding levodopa's plasma half-life of 1 to 3 hours — resulting in complete plasma levodopa washout for 9 to 10 hours each day; the correct rectification is returning to four-times-daily CR dosing at 50/200 mg, which maintains the same total daily dose while reducing the inter-dose interval to approximately 6 hours.
• B) The error was using the CR formulation, which releases levodopa in the acidic gastric environment rather than the proximal jejunum, causing substantial acid degradation of levodopa before it reaches the LAT1 absorption site; the correct rectification is switching back to IR and adding entacapone to achieve the extended duration desired without pH-dependent degradation.
• C) The error was assuming that CR and IR formulations have equivalent bioavailability at the same total daily levodopa dose; CR carbidopa/levodopa has approximately 70 to 75% of the oral bioavailability of IR because slow matrix dissolution delivers levodopa beyond the optimal proximal jejunal LAT1 absorption window during intestinal transit; to achieve equivalent systemic exposure, the total daily CR dose should be approximately 25 to 30% higher than the IR dose — in this patient, 400 mg CR per day provides only approximately 280 to 300 mg effective levodopa exposure, and the total daily CR dose should be increased to approximately 500 to 520 mg (e.g., CR 50/200 mg three times daily or an adjusted regimen) to match the prior IR exposure.
• D) The error was reducing the dosing frequency from four times to twice daily, which eliminated the carbidopa doses that were previously providing additional peripheral AADC inhibition throughout the day; at twice-daily dosing the total daily carbidopa dose falls from 100 mg to 100 mg — technically unchanged — but the per-dose carbidopa level of 50 mg still requires peripheral AADC inhibition re-establishment after each 12-hour interval, producing a window of uninhibited AADC activity that converts levodopa to peripheral dopamine before absorption.
• E) The error was increasing the carbidopa dose per tablet from 25 mg to 50 mg; the higher carbidopa content of the CR formulation oversuppresses peripheral AADC to the extent that it begins inhibiting central AADC at the choroid plexus, reducing CNS conversion of levodopa to dopamine and producing motor deterioration despite adequate plasma levodopa levels.

6. A 65-year-old man with Parkinson's disease is started on selegiline 5 mg twice daily as an adjunct to carbidopa/levodopa for wearing-off. His pharmacist flags a potential interaction and asks the prescribing neurologist whether there is a concern about combining selegiline with levodopa at higher doses. Which of the following best explains the specific safety consideration for selegiline at therapeutic doses for PD, and how it differs from the concern with non-selective MAO inhibitors?

• A) Selegiline at standard PD doses (5 mg twice daily) non-selectively inhibits both MAO-A and MAO-B, producing the full tyramine cheese effect seen with phenelzine and tranylcypromine; the clinical implication is a strict low-tyramine diet requirement identical to that for non-selective MAO inhibitors, and levodopa combination is contraindicated because levodopa-derived dopamine cannot be metabolized by either MAO isoform.
• B) Selegiline selectively inhibits MAO-B at standard PD doses, which does not carry the tyramine interaction of MAO-A inhibition and does not contraindicate levodopa; however, selegiline inhibits the reuptake of norepinephrine in peripheral sympathetic neurons via a separate transporter mechanism, and combination with levodopa raises norepinephrine levels sufficiently to produce hypertensive urgency in patients with pre-existing orthostatic hypotension.
• C) Selegiline has no pharmacologically active metabolites and is entirely eliminated by MAO-B-mediated self-inactivation within the first 4 hours after each dose; consequently it has no meaningful drug interactions at standard doses and the pharmacist's concern is not clinically warranted for this patient.
• D) At standard PD doses (5 mg twice daily), selegiline is selective for MAO-B and does not inhibit MAO-A, avoiding the tyramine cheese effect and the levodopa contraindication seen with non-selective MAO inhibitors; however, selegiline is metabolized to amphetamine and methamphetamine, which are pharmacologically active and can cause cardiovascular stimulation, insomnia, and agitation — particularly at higher doses or in elderly patients; at very high doses (above approximately 20 mg per day), selegiline loses its MAO-B selectivity and begins inhibiting MAO-A, at which point the tyramine interaction becomes relevant; the orally dissolving selegiline formulation (Zelapar) uses presystemic buccal absorption to reduce first-pass amphetamine metabolite generation compared with oral tablets.
• E) Selegiline at any dose irreversibly inhibits both MAO-A and MAO-B in intestinal enterocytes, eliminating the gut wall MAO barrier that normally metabolizes dietary tyramine before it enters the portal circulation; the systemic tyramine exposure from even a modest dietary load can trigger a hypertensive crisis in patients on selegiline regardless of dose, and patients must be counseled on a strict low-tyramine diet equivalent to that required for phenelzine or tranylcypromine.

7. A 72-year-old woman with Parkinson's disease and wearing-off has failed entacapone added to carbidopa/levodopa — she achieved modest improvement initially but continues to have 3 to 4 hours of off time daily. Her neurologist considers switching from entacapone to tolcapone. The patient asks why her neurologist needs to explain special monitoring requirements before starting tolcapone that were not required for entacapone. Which of the following best explains the pharmacological basis for tolcapone's differential toxicity profile compared with entacapone and the monitoring requirement it mandates?

• A) Tolcapone inhibits both peripheral and central COMT, whereas entacapone is peripherally restricted; the CNS COMT inhibition by tolcapone reduces dopamine O-methylation to 3-methoxytyramine within dopaminergic neurons, causing accumulation of reactive dopamine quinones that are directly neurotoxic; liver function monitoring is required because dopamine quinone metabolites are exported to the liver where they cause oxidative hepatocyte injury at therapeutic tolcapone concentrations.
• B) Tolcapone is a potent COMT inhibitor that penetrates the CNS and also inhibits peripheral COMT more durably than entacapone; it has been associated with rare but potentially fatal fulminant hepatocellular necrosis — three fatal cases of hepatic failure were reported post-marketing, leading to a black-box warning and restriction to patients who have failed other adjunctive therapies; the FDA label requires liver function tests at baseline and every 2 to 4 weeks for the first 6 months, then periodically thereafter, and tolcapone must be discontinued if ALT or AST exceeds the upper limit of normal by more than two- to three-fold or if clinical signs of hepatic failure appear; entacapone does not carry this hepatotoxicity risk and requires no liver function monitoring.
• C) Tolcapone and entacapone carry identical hepatotoxicity risk, but tolcapone is given three times daily at 100 mg per dose while entacapone is given with each levodopa dose up to eight times daily; the monitoring requirement reflects the higher total daily tolcapone dose (300 mg) compared with the entacapone dose per administration (200 mg), since cumulative daily COMT inhibition above 500 mg equivalent triggers mandatory hepatic surveillance regardless of which agent is used.
• D) Tolcapone requires liver function monitoring because it is metabolized by glucuronidation in the liver and its glucuronide conjugate competitively inhibits hepatic UGT enzymes responsible for bilirubin conjugation, causing dose-dependent indirect hyperbilirubinemia that can progress to cholestatic jaundice; entacapone shares this metabolic pathway but at a lower affinity, making clinical cholestasis rare at standard entacapone doses.
• E) Tolcapone's hepatotoxicity risk is an indirect consequence of its CNS COMT inhibition: by preventing dopamine O-methylation in the hypothalamus, tolcapone disrupts the dopaminergic regulation of hepatic glycogen metabolism, causing hepatic glycogen depletion and secondary mitochondrial dysfunction that manifests as elevated transaminases; entacapone's peripheral restriction prevents this hypothalamic-hepatic axis disruption and explains the absence of hepatotoxicity with entacapone.

8. A 78-year-old man with advanced Parkinson's disease on carbidopa/levodopa 25/100 mg five times daily undergoes elective colectomy. Perioperative orders include NPO from midnight, and all oral medications are held. He is unable to resume oral intake for 72 hours postoperatively due to ileus. On postoperative day 3 he develops temperature of 40.1°C, severe generalized rigidity, diaphoresis, tachycardia at 118 bpm, and blood pressure instability. Creatine kinase is 4,800 U/L. The surgical team considers neuroleptic malignant syndrome from haloperidol given on postoperative day 1 for agitation, but no antipsychotic had been administered. Which of the following best identifies this syndrome, its mechanism in this patient, and the most appropriate immediate management?

• A) This is a levodopa withdrawal-induced NMS-like syndrome precipitated by 72 hours of levodopa discontinuation in a patient with advanced PD whose endogenous dopamine synthesis capacity is severely depleted; the mechanism is identical to antipsychotic-induced NMS — abrupt dopaminergic deficiency in nigrostriatal and hypothalamic pathways produces the triad of hyperthermia, severe rigidity, and autonomic instability; immediate management is emergent reinstatement of dopaminergic therapy via nasogastric tube (levodopa/carbidopa suspension or crushed tablets in water) combined with aggressive supportive care including cooling, IV hydration, and ICU monitoring; if ileus precludes any enteral route, subcutaneous apomorphine or IV amantadine may bridge until enteral dosing resumes; bromocriptine and dantrolene are used in refractory cases by analogy with antipsychotic NMS management.
• B) This is malignant hyperthermia triggered by the volatile anesthetic agent used for the colectomy; malignant hyperthermia in PD patients has a delayed presentation of 48 to 72 hours because nigrostriatal dopamine depletion reduces the normal metabolic brake on ryanodine receptor-mediated calcium release; immediate management is dantrolene 2.5 mg/kg IV bolus with supplemental doses every 5 minutes until temperature normalizes, and levodopa discontinuation should be maintained because dopaminergic stimulation worsens ryanodine receptor calcium efflux.
• C) This is serotonin syndrome precipitated by the combination of tramadol (prescribed for postoperative pain) and the residual MAO-B inhibitory effect of rasagiline, which the patient was taking before surgery; the elevated CK reflects serotonin-induced muscle hyperactivity rather than dopaminergic rigidity; immediate management is cyproheptadine 12 mg orally, discontinuation of tramadol, and observation; levodopa reinstatement is not urgently indicated as serotonin syndrome resolves within 24 hours of offending agent removal.
• D) This is postoperative sepsis with secondary rhabdomyolysis from immobility, and the rigidity reflects early septic encephalopathy rather than a dopaminergic syndrome; the correct management is blood cultures, broad-spectrum antibiotics, and IV fluid resuscitation; the elevated CK reflects myonecrosis from pressure injury during prolonged supine positioning and will resolve with hydration and mobilization; levodopa reinstatement can be deferred until oral intake resumes as a routine medication reconciliation step.
• E) This is neuroleptic malignant syndrome from the haloperidol given postoperatively, but the delayed presentation at 72 hours reflects the accumulation of haloperidol's active reduced metabolite (haloperidol reduced) which has a longer half-life than the parent drug; immediate management is dantrolene and bromocriptine; levodopa should not be restarted until the NMS has fully resolved because dopaminergic stimulation during the acute NMS phase paradoxically worsens hyperthermia through hypothalamic dopamine receptor overstimulation.

9. A 64-year-old woman with a 10-year history of Parkinson's disease has moderately disabling peak-dose dyskinesia — continuous choreiform movements of the arms during her on period — and also experiences significant wearing-off that begins 45 minutes before each of her five daily carbidopa/levodopa doses. She is on carbidopa/levodopa 25/100 mg five times daily without any adjunctive agents. Her neurologist presents two management options: Option 1 is to reduce each levodopa dose by 25 mg while adding a dose to maintain frequency; Option 2 is to add extended-release amantadine (Gocovri 274 mg at bedtime) without changing the levodopa regimen. Which of the following best explains the mechanistic basis and clinical trade-off of each approach, and identifies why amantadine is generally preferred when both wearing-off and dyskinesia are present simultaneously?

• A) Option 1 (levodopa dose reduction) targets dyskinesia by reducing peak striatal dopamine concentrations, which reduces the amplitude of the sensitized direct pathway MSN response, but the dose reduction simultaneously lowers the trough plasma levodopa concentration, worsening wearing-off and reducing total daily on-time; Option 2 (amantadine) targets the NMDA receptor-mediated glutamatergic component of dyskinesia downstream of the dopamine peak without reducing levodopa levels, preserving the therapeutic plasma levodopa concentration that prevents wearing-off — this is why amantadine is preferred when the patient has both dyskinesia and wearing-off, since it reduces dyskinesia amplitude without shortening on-time.
• B) Option 1 (levodopa dose reduction) eliminates peak-dose dyskinesia entirely by moving striatal dopamine below the dyskinesia threshold at all times, which also completely eliminates wearing-off because the lower constant dopamine level keeps the patient in a stable sub-dyskinetic but fully therapeutic on state; Option 2 (amantadine) is preferred only in patients without wearing-off because its NMDA antagonism reduces the therapeutic response to levodopa at trough concentrations, worsening motor function during the pre-dose period in patients who already have wearing-off.
• C) Option 1 (levodopa dose reduction) and Option 2 (amantadine) have identical efficacy for reducing dyskinesia severity but different side effect profiles; the choice between them is based entirely on patient preference for tablet burden versus injection-site reactions, since amantadine requires subcutaneous administration in its extended-release formulation at bedtime.
• D) Option 2 (amantadine) is preferred because it directly inhibits the D1 receptor in sensitized direct pathway MSNs, reducing the amplitude of the dyskinetic movement signal at its origin; Option 1 (levodopa dose reduction) is less effective because reducing levodopa dose lowers D2 receptor occupancy in the indirect pathway without affecting the sensitized D1-mediated direct pathway that drives dyskinesia, producing wearing-off without any meaningful dyskinesia benefit.
• E) Option 2 (amantadine) is generally preferred over dose reduction when both wearing-off and dyskinesia coexist because amantadine's NMDA receptor antagonism in the striatum attenuates the potentiated corticostriatal glutamatergic drive at sensitized direct pathway medium spiny neurons — reducing dyskinesia amplitude — without altering the plasma levodopa pharmacokinetics that determine the wearing-off threshold; levodopa dose reduction reduces dyskinesia by lowering peak dopamine concentrations but simultaneously shortens effective on-time by reducing trough levodopa, worsening wearing-off; in a patient who already has inadequate on-time from wearing-off, further shortening on-time by dose reduction is clinically unacceptable unless the dyskinesia is so severe that it itself impairs function more than the wearing-off.

10. A 56-year-old man with Parkinson's disease was started on ropinirole 3 mg three times daily 18 months ago as first-line therapy, with the rationale of reducing long-term dyskinesia risk through reduced early levodopa exposure. He now presents with visual hallucinations — vivid, formed images of people in his home that he initially recognized as non-threatening but now finds frightening — and his wife reports he has recently become confused during evening hours. His motor control on ropinirole has been adequate. Which of the following best identifies the correct management approach, explains why this complication changes the risk-benefit calculation for continued agonist monotherapy, and describes the transition strategy?

• A) The hallucinations represent ropinirole-induced serotonin syndrome from its partial agonist activity at 5-HT2A receptors in the visual cortex; the correct management is adding quetiapine 25 mg at bedtime as a 5-HT2A inverse agonist to suppress the visual hallucinations while continuing ropinirole for motor control; levodopa substitution is not indicated because the hallucinations are serotonergic rather than dopaminergic in mechanism.
• B) The hallucinations are early Lewy body dementia rather than a drug effect; the correct management is formal neuropsychological testing, discontinuation of all dopaminergic medications, and initiation of rivastigmine; ropinirole should be discontinued immediately without substitution because dopaminergic medications universally worsen Lewy body dementia psychosis regardless of drug class.
• C) Dopamine agonist-induced hallucinations and neuropsychiatric effects are more likely and more severe in patients with underlying cognitive vulnerability, and the development of frightening hallucinations and evening confusion is a clinically significant agonist intolerance requiring discontinuation of ropinirole; the transition strategy is to gradually withdraw ropinirole while simultaneously introducing carbidopa/levodopa at doses sufficient to maintain motor control — levodopa is substantially less likely than dopamine agonists to produce hallucinations at motor-effective doses in patients without severe pre-existing cognitive impairment — and if hallucinations persist after agonist discontinuation, low-dose quetiapine or pimavanserin (a selective 5-HT2A inverse agonist that does not worsen motor function) can be added; the dyskinesia risk accepted by this transition is justified by the severity of the neuropsychiatric adverse effects.
• D) Ropinirole should be continued at its current dose because the hallucinations are a transient adaptation response to dopamine agonist therapy that typically resolves after 6 to 8 weeks as thalamic filtering of dopaminergic visual signals is re-established; adding clonazepam 0.5 mg at bedtime will reduce the evening confusion by stabilizing thalamic oscillations during the adaptation period without interfering with ropinirole's motor benefit.
• E) The hallucinations indicate that ropinirole dose is supratherapeutic for this patient's current striatal dopamine receptor density; the correct management is reducing ropinirole to 1 mg three times daily, which will reduce mesolimbic D3 stimulation below the hallucination threshold while maintaining sufficient D2 motor pathway stimulation; if motor control deteriorates at the lower dose, carbidopa/levodopa 10/100 mg can be added at bedtime only, as nocturnal levodopa doses do not contribute to dyskinesia risk.

11. A 70-year-old man with Parkinson's disease and moderate COPD (FEV1 58% predicted, FEV1/FVC 0.62) continues to experience two to three unpredictable off episodes per week despite optimized oral carbidopa/levodopa and rasagiline. His movement disorders neurologist considers levodopa inhalation powder (Inbrija) as a rescue agent for off episodes. His pulmonologist raises concerns about the pulmonary route. Which of the following best identifies the specific pulmonary safety concern with inhaled levodopa in this patient, the required pre-prescribing evaluation, and the preferred alternative rescue strategy if inhaled levodopa is contraindicated?

• A) Inhaled levodopa is contraindicated in patients with any degree of airflow obstruction because pulmonary AADC activity is proportional to FEV1, and in patients with COPD the reduced alveolar surface area means that a greater fraction of the inhaled dose is converted to dopamine in the bronchial epithelium before systemic absorption, producing local bronchial dopaminergic vasoconstriction that triggers bronchospasm; the alternative is sublingual apomorphine, which avoids all pulmonary exposure.
• B) Inhaled levodopa is contraindicated in COPD patients because the dry powder formulation contains lactose as a carrier particle that triggers mast cell degranulation in sensitized COPD airways, causing IgE-mediated bronchoconstriction; patients must undergo skin prick testing for lactose hypersensitivity before any dry powder inhaler can be prescribed; the alternative rescue strategy is subcutaneous apomorphine injection.
• C) Inhaled levodopa is safe in all COPD patients because the alveolar deposition of dry powder particles is actually improved in obstructed airways due to reduced central airway turbulence and enhanced peripheral deposition by Brownian motion; pulmonary function testing before prescribing is recommended only as a baseline measure and does not change prescribing decisions; patients with FEV1 below 30% predicted should use a spacer device with the Inbrija inhaler.
• D) Inhaled levodopa (Inbrija) carries a risk of bronchospasm in patients with underlying pulmonary disease including COPD and asthma; the FDA label requires that patients be evaluated for underlying pulmonary disease before prescribing and that spirometry be performed; in patients with significant airflow obstruction such as this patient (FEV1 58% predicted), the risk of bronchospasm may outweigh the benefit of the inhaled route, and subcutaneous apomorphine is the appropriate alternative rescue strategy for off episodes — it produces reliable, rapid motor benefit within 5 to 15 minutes of injection, bypassing any pulmonary risk entirely, though it requires patient training for self-injection and carries its own side effects including injection site nodules and orthostatic hypotension.
• E) Inhaled levodopa does not carry any pulmonary risk in patients with stable COPD because the drug is absorbed within the alveoli and does not contact the bronchial smooth muscle; the pulmonologist's concern is not clinically warranted; the only pre-prescribing evaluation required for Inbrija in COPD patients is a chest radiograph to exclude active pulmonary infection that might reduce alveolar surface area and reduce drug bioavailability below therapeutic levels.

12. A 68-year-old woman with advanced Parkinson's disease has been on levodopa-carbidopa intestinal gel (LCIG) infusion for 14 months with excellent motor control and marked reduction in off time. She now presents with progressive numbness and tingling in both feet over the past 3 months, with distal weakness emerging over the last 4 weeks. Nerve conduction studies confirm a length-dependent axonal sensorimotor peripheral neuropathy. Her neurologist considers whether this represents a complication of LCIG therapy. Which of the following best identifies the proposed mechanism of LCIG-associated neuropathy, the specific component of the formulation implicated, and the appropriate management response?

• A) The neuropathy is a direct toxic effect of high levodopa concentrations on peripheral axons; at the infusion rates required for continuous jejunal delivery (typically 60 to 100 mg levodopa per hour), plasma levodopa peaks reach levels that directly inhibit axonal mitochondrial complex I, producing length-dependent oxidative axonal injury; management is reducing the infusion rate by 30% and supplementing with alpha-lipoic acid as a mitochondrial antioxidant.
• B) LCIG-associated peripheral neuropathy has been attributed to high cumulative carbidopa doses delivered at the continuous infusion rates required for LCIG — typically substantially higher than the carbidopa doses achievable with oral therapy — which may deplete pyridoxal-5'-phosphate (vitamin B6) systemically through covalent binding of carbidopa to PLP, impairing PLP-dependent enzyme systems including those involved in myelin synthesis and peripheral nerve axonal maintenance; management includes measurement of plasma homocysteine and methylmalonic acid to assess functional B12 and folate status (hyperhomocysteinemia is a risk factor for neuropathy), vitamin B12 and folate supplementation if deficient, and consideration of reducing the LCIG infusion rate or transitioning to an alternative advanced therapy such as deep brain stimulation if neuropathy progresses.
• C) LCIG-associated neuropathy is caused by the polyvinyl chloride (PVC) plasticizer DEHP leaching from the PEG-J tube into the jejunal lumen; DEHP is absorbed by the proximal jejunum and circulates to peripheral nerves where it inhibits sphingomyelinase, disrupting myelin lipid metabolism; management is replacing the PEG-J tube with a DEHP-free silicone catheter, which resolves the neuropathy within 6 to 8 weeks without dose adjustment.
• D) LCIG-associated neuropathy reflects accelerated nigrostriatal degeneration spreading to the peripheral nervous system in patients with advanced PD; it is a disease-progression phenomenon rather than a drug complication, and no pharmacological intervention modifies its course; management is patient counseling and physiotherapy, and LCIG should be continued because its motor benefits outweigh the neuropathy risk in all patients.
• E) The neuropathy is caused by the continuous levodopa infusion maintaining plasma levels above 3 micromol/L for 16 hours daily, which chronically saturates the LAT1 transporter in peripheral nerve endothelial cells, blocking the entry of tyrosine and phenylalanine into peripheral Schwann cells and producing a peripheral demyelinating neuropathy from amino acid deprivation; management is adding a low-protein diet to reduce competition between plasma amino acids and levodopa for peripheral LAT1 transport.

13. A 60-year-old man with a 12-year history of Parkinson's disease is referred for evaluation of dyskinesia that has not responded to extended-release amantadine at 274 mg nightly for 3 months. Careful review of his motor diary and a video recording reveal a pattern in which involuntary movements — predominantly in the legs, with a ballistic, high-amplitude character — appear within 10 to 15 minutes after each levodopa dose while his motor function is still subtherapeutic, resolve briefly when full motor benefit is achieved at peak dose, and then reappear as the dose wears off, again when motor function is subtherapeutic. During the peak period between these two windows he has good motor control with minimal dyskinesia. Which of the following best identifies this dyskinesia pattern, explains its pharmacodynamic basis, and describes why it responds differently to management compared with peak-dose dyskinesia?

• A) This is diphasic dyskinesia (also called D-I-D: dyskinesia-improvement-dyskinesia), characterized by involuntary movements appearing at the beginning and end of each dose cycle when plasma levodopa is in an intermediate rising or falling concentration range — neither low enough for an off state nor high enough for peak benefit — rather than at peak plasma concentrations; the pharmacodynamic basis is hypothesized to involve differential sensitization of striatal circuits at intermediate dopamine concentrations, possibly reflecting a window of maximal imbalance between direct and indirect pathway activation; critically, because diphasic dyskinesia occurs at low-to-intermediate plasma levodopa concentrations rather than at peak, the strategies effective for peak-dose dyskinesia — amantadine and levodopa dose reduction — are either ineffective or paradoxically worsen diphasic dyskinesia by increasing the time the patient spends in the intermediate concentration range; management strategies for diphasic dyskinesia focus on eliminating the intermediate plasma levodopa concentration window through continuous dopaminergic delivery (LCIG or apomorphine infusion) or deep brain stimulation.
• B) This is off-period dystonia occurring at the beginning and end of each dose cycle when dopamine receptor stimulation is absent; it is distinguished from peak-dose dyskinesia by its dystonic rather than choreiform character; management is identical to wearing-off management — COMT inhibitors, MAO-B inhibitors, and extended-release formulations — all of which extend the duration of adequate dopamine levels and reduce the time spent in the off state when dystonia occurs; amantadine is ineffective for off-period dystonia because its NMDA mechanism requires dopamine receptor co-activation to exert its anti-dyskinetic effect.
• C) This is tardive dyskinesia from the patient's prior exposure to metoclopramide prescribed for gastroparesis 5 years ago; the D-I-D pattern reflects a pharmacodynamic interaction between residual D2 receptor upregulation from tardive dyskinesia and the pulsatile dopamine delivery of oral levodopa; management is clonazepam and valbenazine (a VMAT2 inhibitor); levodopa dose manipulation is not appropriate because tardive dyskinesia is independent of current dopaminergic therapy intensity.
• D) This is peak-dose dyskinesia that is unusually treatment-resistant because this patient has a rare genetic variant in the NMDA receptor GluN2B subunit that reduces amantadine binding affinity by 90%; the correct management is switching to memantine, a more potent NMDA antagonist with nanomolar GluN2B affinity that is not affected by this variant; the D-I-D appearance is an artifact of his motor diary recording, and a formal dyskinesia rating scale in clinic would confirm the characteristic peak-dose timing.
• E) This is wearing-off misclassified as dyskinesia; the involuntary movements at the beginning and end of each dose cycle are actually severe parkinsonian tremor that worsens in the subtherapeutic levodopa concentration window; the resolution at peak dose reflects adequate dopaminergic suppression of tremor; the management is identical to wearing-off — shortening the dosing interval and adding entacapone — and amantadine is not indicated because it does not affect levodopa pharmacokinetics.